Applying to Clinical Trial: A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma

Contact this trialFirst, we need to learn more about you.

CAR T-cell Therapy

PBCAR269A for Multiple Myeloma

Recruiting2 awardsPhase 1

Boston, Massachusetts

This trial is testing a new drug, PBCAR269A, for safety and effectiveness in treating adults with relapsed or refractory myeloma. The trial is divided into two groups, with one group receiving PBCAR269A and nirogacestat, and the other group receiving just PBCAR269A. The goal is to see if PBCAR269A is safe and effective in treating myeloma.

Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.

We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our and .

Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.

By clicking start, you agree to our